Climb Bio, Inc.
CLYM
$1.74
$0.106.10%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 41.86% | -27.92% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 39.48% | -53.61% | |||
| Operating Income | -39.48% | 53.61% | |||
| Income Before Tax | -48.72% | 58.30% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -48.72% | 58.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -48.72% | 58.30% | |||
| EBIT | -39.48% | 53.61% | |||
| EBITDA | -39.45% | -- | |||
| EPS Basic | -47.82% | 58.38% | |||
| Normalized Basic EPS | -47.94% | 59.69% | |||
| EPS Diluted | -47.82% | 58.38% | |||
| Normalized Diluted EPS | -47.94% | 59.69% | |||
| Average Basic Shares Outstanding | 0.62% | 0.18% | |||
| Average Diluted Shares Outstanding | 0.62% | 0.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||